ViSci – Completion of the Last Patient Treatment in a Phase I/IIa Clinical Trial

The Company hereby announces that on April 25, 2017, ViSci Ltd., a subsidiary of the Company, announced that the last participant in the Phase I/IIa clinical trial conducted in the United States under the Food and Drug Administration (FDA) has completed his treatment, and believes that final clinical results of the trial are expected in the second half of 2017.

Link to complete article

Link to Newsroom

Comments are closed